Evidence map›Paper›PMID 34174331›Full record

ArticleMagnetic resonance imaging2021

Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths.

Heather M Whitney, Karen Drukker, Alexandra Edwards, John Papaioannou, Milica Medved, Gregory Karczmar, Maryellen L Giger

Abstract read
In one paragraph

Article in Magnetic resonance imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heather M WhitneyDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America; Department of Physics, Wheaton College, Wheaton, IL 60187, United States of America. Electronic address: hwhitney@uchicago.edu.
Karen DrukkerDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America.
Alexandra EdwardsDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America.
John PapaioannouDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America.
Milica MedvedDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America.
Gregory KarczmarDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America.
Maryellen L GigerDepartment of Radiology, The University of Chicago, Chicago, IL 60637, United States of America. Electronic address: m-giger@uchicago.edu.

Funding

RESEARCH TRAINING IN MEDICAL PHYSICST32EB002103 · NIBIB · UNIVERSITY OF CHICAGO · PI ARMATO, SAMUEL G. · 2003 to 2019
$4.7M
Quantitative Image Analysis for Assessing Response to Breast Cancer TherapyU01CA195564 · NCI · UNIVERSITY OF CHICAGO · PI GIGER, MARYELLEN L. · 2015 to 2019
$2.5M
Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRIR01CA167785 · NCI · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S., NEWSTEAD, GILLIAN · 2013 to 2017
$2.4M
Assessment of Repeatability and Robustness of Radiomics in Breast Cancer ImagingR15CA227948 · NCI · WHEATON COLLEGE · PI WHITNEY, HEATHER M · 2019 to 2019
$397k
Protected Radiomics Analysis Commons for Deep Learning in Biomedical DiscoveryS10OD025081 · OD · UNIVERSITY OF CHICAGO · PI GIGER, MARYELLEN L. · 2018 to 2018
$339k
NCI NIH HHS R01 CA167785NCI NIH HHS R15 CA227948NCI NIH HHS U01 CA195564NIBIB NIH HHS T32 EB002103NIH HHS S10 OD025081
6 · The paper itself

Abstract

Radiomic features extracted from breast lesion images have shown potential in diagnosis and prognosis of breast cancer. As medical centers transition from 1.5 T to 3.0 T magnetic resonance (MR) imaging, it is beneficial to identify potentially robust radiomic features across field strengths because images acquired at different field strengths could be used in machine learning models. Dynamic contrast-enhanced MR images of benign breast lesions and hormone receptor positive/HER2-negative (HR+/HER2-) breast cancers were acquired retrospectively, yielding 612 unique cases: 150 and 99 benign lesions imaged at 1.5 T and 3.0 T, and 223 and 140 HR+/HER2- cancerous lesions imaged at 1.5 T and 3.0 T, respectively. In addition, an independent set of seven lesions imaged at both field strengths, three benign lesions and four HR+/HER2- cancers, was analyzed separately. Lesions were automatically segmented using a 4D fuzzy c-means method; thirty-eight radiomic features were extracted. Feature value distributions were compared by cancer status and imaging field strength using the Kolmogorov-Smirnov test. Features that did not demonstrate a statistically significant difference were considered to be potentially robust. The area under the receiver operating characteristic curve (AUC), for the task of classifying lesions as benign or HR+/HER2- cancer, was determined for each feature at each field strength. Three features were found to be both potentially robust across field strength and of high classification performance, i.e., AUCs statistically greater than 0.5 in the classification task: one shape feature (irregularity), one texture feature (sum average) and one enhancement variance kinetics features (enhancement variance increasing rate). In the demonstration set of lesions imaged at both field strengths, two of the three potentially robust features showed qualitative agreement across field strength. These findings may contribute to the development of computer-aided diagnosis models that are robust across field strength for this classification task.

Indexed as

Breast NeoplasmsMagnetsBreastContrast MediaFemaleHormonesHumansMagnetic Resonance ImagingRetrospective StudiesContrast MediaHormonesBreast cancerComputer-aided diagnosisDCE-MRIField strengthHR+/HER2-Radiomics

Identifiers

PMID34174331
PMCPMC8386988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.